# Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin

Study · id `cardio:ct-nct03299296` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03299296](<https://clinicaltrials.gov/study/NCT03299296>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03299296

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 100 participants.

## Technical summary

Registry record NCT03299296. Randomized; single masking; primary purpose prevention. Start 2017-01-01 (actual); primary completion 2018-01-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03299296, source copy `cardio:ctgov-nct03299296-2017-10-17`, retrieved 2026-10-31)
- Started: 2017-01-01 (actual) (ClinicalTrials.gov record NCT03299296, source copy `cardio:ctgov-nct03299296-2017-10-17`, retrieved 2026-10-31)
- Primary completion: 2018-01-30 (anticipated) (ClinicalTrials.gov record NCT03299296, source copy `cardio:ctgov-nct03299296-2017-10-17`, retrieved 2026-10-31)
- Completion: 2018-03-30 (anticipated) (ClinicalTrials.gov record NCT03299296, source copy `cardio:ctgov-nct03299296-2017-10-17`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03299296-2017-10-17`, retrieved 2026-10-31)

## The registry's words

- Brief title: Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin
- Condition: Thromboses, Deep Vein
- Condition: Surgery--Complications
- Intervention (Drug): Rivaroxaban 10 Milligrams
- Intervention (Drug): Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe
- Lead sponsor: Ahmed AbdelMoneim Hassan Ali
- Lead sponsor class: OTHER
- Collaborator: Beni-Suef University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry lists this organization as a collaborator: Beni-Suef University (`cardio:org-beni-suef-university`)

## Provenance

Content hash: 66ffb4d929063536f99967c0b9fef6b1a5ec46fb4903693dc34faceda3a588cd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
